Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
163 results about "Arteriolar Vasoconstriction" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Vasoconstriction is the narrowing of the blood vessels resulting from contraction of the muscular wall of the vessels, in particular the large arteries and small arterioles.
Methods and devices for the non-thermal, electrically-induced closure of blood vessels
ActiveUS8105324B2Less discomfortSelectively induce hemostasis within blood vesselsElectrotherapySurgical instruments for heatingElectricityArteriolar Vasoconstriction
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Systems and methods using vasoconstriction for improved thermal treatment of tissues
InactiveUS6840954B2Improve the effectiveness of treatmentEnhance such thermal treatmentAnti-incontinence devicesSurgical instruments for heatingArteriolar VasoconstrictionTreatment effect
The present invention enhances the effectiveness of treatment of support tissue structures. Generally, such tissue structures support organs and hold the organs in their proper position for appropriate functioning. When such tissue structures become weak, hyper-elastic, and / or excessively lengthy, the organs of are no longer supported in their proper position. This often leads to physical manifestations such as incontinence, hernias, and the like. Remedies often involve thermal treatment of the support tissue structures, such as thermally inducted controlled shrinkage, contraction, or stiffening of the support tissue structure. To enhance such thermal treatment and diminish the possibility of undesirable heating and damage to nearby tissue surfaces, vasoconstrictive agents are used.
Owner:ASTORA WOMENS HEALTH
Controlled heat transfer with mammalian bodies
Methods, computer programming and devices for transferring heat to and / or from a body portion of a mammal are provided. One approach includes directly determining a state of vasoconstriction or vasodilation in a portion of a body, and supplying heat to the portion of the body when vasoconstriction is determined, and removing heat from the portion of the body when vasodilation is determined. The body portion preferably includes specific heat exchange vasculature. In another approach, a transition of the body portion from a state of vasodilation to vasoconstriction is determined and the body portion is then actively kept in a state of vasodilation while removing heat therefrom.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
InactiveUS20030087962A1Control inflammationPain controlBiocideKallidin/bradykinin ingredientsArteriolar VasoconstrictionInflammation Process
A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and / or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.
Owner:OMEROS CORP
Controlled heat transfer with mammalian bodies
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
ActiveUS7932356B1Increase oxygenationHigh sensitivityPeptide/protein ingredientsMammal material medical ingredientsArteriolar VasoconstrictionCross-link
A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin, uncross-linked tetrameric hemoglobin, and plasma protein impurities effectively. Addition of N-acetyl cysteine after heat treatment and optionally before heat treatment maintains a low level of met-hemoglobin. The heat stable cross-linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal carcinoma and esophageal cancer. Another application is heart preservation in situations where there is a lack of oxygen supply in vivo, such as in heart transplant or oxygen-deprived heart.
Owner:BILLION KING INT
Controlled heat transfer with mammalian bodies
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Methods and Devices For the Non-Thermal, Electrically-Induced Closure of Blood Vessels
ActiveUS20080188846A1Minimal electrochemical damageLess discomfortElectrotherapySurgical instruments for heatingElectricityArteriolar Vasoconstriction
Methods and devices for the non-thermal, electrically-induced temporary or permanent closure of blood vessels. The subject methods and devices employ pulsed electrical energy according to a defined regime to effect controlled occlusion of targeted blood vessels without heating the vessel and with minimal damage to adjacent tissue. The extent of vessel closure, i.e., temporary (vasoconstriction) or permanent (thrombosis), is controlled based on the manipulation of various parameters of the electrical stimulation regime as well as the configuration of the electrodes used to apply the regime.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Use of relaxin treat diseases related to vasoconstriction
InactiveUS6723702B2Safety profileImprove securityElectrotherapyPeptide/protein ingredientsArteriolar VasoconstrictionVascular disease
The invention related to methods of treating disease related to vasoconstriction that is a major factor in hypertensive vascular diseases and vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is useful in treating a wide variety of diseases relating to vasoconstriction.
Owner:RUTGERS THE STATE UNIV +2
Patient temperature regulation method and apparatus
InactiveUS6843800B1Lower body temperatureProhibiting interventionHydroxy compound active ingredientsOther blood circulation devicesVeinArteriolar Vasoconstriction
A device and method for providing body cooling. The cooling device applies cooling to blood flowing in a vena cavae that is then distributed throughout the body. The cooling can be assisted by use of thermoregulatory drugs or warming devices to prevent shivering and vasoconstriction.
Owner:PHILIPS ELECTRONICS NORTH AMERICA
New use for cannabinoid-containing plant extracts
The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of diseases or conditions that are alleviated by blockade of one or more types of TRP channel. Preferably the subset of TRP channel that is blockaded is the TRPA channel. More preferably the TRPA channel is the TRPA1 channel. Preferably the diseases or conditions to be prevented or treated include: neuropathic pain, inflammation or vasoconstriction. Alternatively the TRP channel that is blockaded is the TRPM channel. More preferably the TRPM channel is the TRPM8 channel. Preferably the diseases or conditions to be prevented or treated are cancer. More preferably the cancers to be treated include: cancer of the prostate, cancer of the breast, cancer of the colon, cancer of the lung or cancer of the skin. Alternatively the TRP channel that is blockaded is the TRPV channel. More preferably the TRPV channel is the TRPV1 channel. Preferably the diseases or conditions to be prevented or treated include neuropathic pain, inflammation or vasoconstriction.
Owner:GW PHARMA LTD
Method for treating cardiovascular diseases using rho kinase inhibitor compounds
This invention is directed to methods of preventing or treating diseases or conditions associated with excessive cell proliferation, remodeling, inflammation, and vasoconstriction. Particularly, this invention is directed to methods of treating cardiovascular diseases or conditions such as stent restenosis and thrombosis, vascular thrombosis, cerebral vasospasm, atherosclerosis, systemic hypertension, cardiac hypertrophy, and sexual dysfunction. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel Rho kinase inhibitor compound to treat the disease.
Owner:INSPIRE PHARMA
Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
ActiveUS7989593B1Increase oxygenationHigh sensitivityPeptide/protein ingredientsMammal material medical ingredientsArteriolar VasoconstrictionWhite blood cell
A high temperature-stable and highly purified cross-linked (optionally ≧70% β-β linked) tetrameric hemoglobin with high efficiency of oxygen delivery suitable for use in mammals without causing renal injury and vasoconstriction is provided. The dimeric form of hemoglobin is degenerated and purification processes are performed on red blood cells from whole blood. Controlled hypotonic lysis in an instant cytolysis apparatus prevents lysis of white blood cells. Nucleic acids from white blood cells and phospholipids impurities are not detected. Blocking of reactive sulfhydryl groups by a sulfhydryl reagent is performed in an oxygenated environment. Flowthrough column chromatography removes different plasma protein impurities. N-acetyl cysteine is added to the cross-linked tetrameric hemoglobin to maintain a low level of met-hemoglobin. The stabilized hemoglobin is preserved in an infusion bag with aluminum overwrap to prevent formation of inactive met-hemoglobin from oxygen intrusion. The product finds use in tissue oxygenation and cancer treatment.
Owner:BILLION KING INT
Use of high dose concentrations of gaseous nitric oxide
InactiveUS20080193566A1Efficient procedureBiocideBronchoscopesRESPIRATORY DISTRESS SYNDROME ADULTArteriolar Vasoconstriction
The invention relates to a methods and devices of delivering gaseous nitric oxide to a mammal or surface at a concentration ranging from about 1000 ppm to about 50,000 ppm of gaseous nitric oxide. Different conditions which can be treated by high dosage administration of gNO include but are not limited to: topical treatments with gNO, cosmetic applications of gNO, vasodilation conditions with gNO, inhalation treatments with gNO, treatments of the blood with gNO, treatment of the skin or tissue with gNO, treatment of infections with gNO, treatment of inflammation on or within the body, and treatments of biofilms with gNO. Other conditions, aliments, or symptoms that may be treated with high dosage gNO include bronchoconstriction, reversible pulmonary vasoconstriction, asthma, pulmonary hypertension, adult respiratory distress syndrome (ARDS), and persistent pulmonary hypertension of the newborn (PPHN).
Owner:PULMONOX TECH
Method for treating pulmonary diseases using rho kinase inhibitor compounds
Owner:INSPIRE PHARMA
Arterial endothelial function measurement method and apparatus
ActiveUS20060264755A1High outputEasy to detectOrgan movement/changes detectionInfrasonic diagnosticsArteriolar VasoconstrictionArterial diameter
A “relaxoscope” (100) detects the degree of arterial endothelial function. Impairment of arterial endothelial function is an early event in atherosclerosis and correlates with the major risk factors for cardiovascular disease. An artery (115), such as the brachial artery (BA) is measured for diameter before and after several minutes of either vasoconstriction or vasorelaxafion. The change in arterial diameter is a measure of flow-mediated vasomodification (FMVM). The relaxoscope induces an artificial pulse (128) at a superficial radial artery (115) via a linear actuator (120). An ultrasonic Doppler stethoscope (130) detects this pulse 10-20 cm proximal to the point of pulse induction (125). The delay between pulse application and detection provides the pulse transit time (PTT). By measuring PTT before (160) and after arterial diameter change (170), FMVM may be measured based on the changes in PTT caused by changes in vessel caliber, smooth muscle tone and wall thickness.
Owner:RGT UNIV OF CALIFORNIA
Patient temperature regulation method and apparatus
InactiveUS7101386B2Increase flexibilityLower body temperatureHydroxy compound active ingredientsOther blood circulation devicesVeinArteriolar Vasoconstriction
Owner:PHILIPS ELECTRONICS NORTH AMERICA
Helicid soft capsule and its preparation method
InactiveCN1535690ALessen the severity of seizuresAlpha-wave exponential decreaseOrganic active ingredientsNervous disorderConvulsionSedative Effects
The present invention provides a helical soft capsule. Every capsule contains 5-200mg of helical, the rest is solvent matrix, the described solvent matrix is one of PEG 300-1000, propylene alcohol, soybean oil and peanut oil or their composition. According to the requirements the medicinal color matter and flavor agent can be added into its liquid medicine. Said invented soft capsule has the sedation, can obviously reduce coriamyrtin convulsion incidence rate, prolong its generative latent period, reduce frequency of attack and shorten the time and process of attack, and has the actions of stopping pain and resisting inflammation, and has a certain action of relieving vasoconstriction and raising oxygen consumption of heart muscle, and its biological utilization rate can be raised by 10-59%.
Owner:KUNMING ZIJIAN BIOTECH
Therapeutic Avenanthramide Compounds
InactiveUS20070254055A1Delay disease progressionAvoid formingOrganic active ingredientsBiocideArteriolar VasoconstrictionCell adhesion
Methods and compositions are disclosed for inhibiting proliferation of human colon adenocarcinoma cells, reducing pro-inflammatory molecules, adhesion molecules, and vascular smooth muscle cell proliferation, and for increasing NO production. The present invention describes the use of phenolic compositions, purified from oats or synthetically produced, to decrease the effective amount of pro-inflammatory molecules and / or cell adhesion molecules. Alternatively, an alcoholic extract or concentrate from oats can be used. The methods of the present invention can be used as a treatment or prophylaxis of a wide variety of disorders associated with inflammatory states and / or with a lack of or need for nitric oxide (NO), such as inflammatory conditions, pain, free radical associated disorders, cardiovascular diseases, autoimmune disorders, pathological platelet aggregation, pathological vasoconstriction, vascular effects of diabetes, stroke, atherosclerosis, hypertension, abnormal vasospasm, and restenosis after angioplasty.
Owner:TRUSTEES OF TUFTS COLLEGE D B A TUFTS UNIV
Methods for treating a breach or puncture in a blood vessel
InactiveUS20030078234A1CessationIncreased riskBiocideSolution deliveryArteriolar VasoconstrictionVascular structure
Owner:MARINE POLYMER TECH
Patient temperature regulation method and apparatus
InactiveUS20060124141A1Increase flexibilityLower body temperatureDiagnosticsCatheterArteriolar VasoconstrictionVein
A device and method for providing body cooling. The cooling device applies cooling to blood flowing in a vena cavae that is then distributed throughout the body. The cooling can be assisted by use of thermoregulatory drugs or warming devices to prevent shivering and vasoconstriction.
Owner:ZOLL CIRCULATION
Topical phenyl-epinephrine Rosacea treatment
InactiveUS20050256204A1Safe and effectiveEffective temporary reliefBiocideOrganic active ingredientsArteriolar VasoconstrictionDisease
A near-permanent skin treatment includes photothermolysis of reddened facial skin to induce ischemia. Reperfusion of the photothermolysis treated skin is inhibited by following with regular applications of phenyl-epinephrine carried in a lotion until vascular necrosis is complete. Alternatively, a temporary treatment for reddened facial skin includes only cosmetic as-needed applications of phenyl-epinephrine carried in lotion to induce vasoconstriction in Rosacea and other similarly embarrassing skin disorders.
Owner:BITTER PATRICK H SR
Use of relaxin to treat diseases related to vasoconstriction
InactiveUS20040266685A1Safety profileImprove securityPeptide/protein ingredientsRelaxinsArteriolar VasoconstrictionDisease
Owner:THE UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY ROBERT WOOD JOHNSON MEDICAL SCHOOL +2
Flavone derivative, preparation method and application
InactiveCN101148444AStrong inhibitory activitySimple structureOrganic active ingredientsSenses disorderDiseaseArteriolar Vasoconstriction
The present invention relates to flavone derivatives in the structure as shown, and their preparation process and intermediate. These compounds have excellent PDE5 inhibiting activity, and may be applied in treating sexual disorder and vasoconstriction related diseases.
Owner:TOPHARMAN SHANGHAI +2
Compositions and methods for modulation of vascular structure and/or function
InactiveUS20020019367A1Minimizing blood lossCessationBiocideSolution deliveryArteriolar VasoconstrictionVascular structure
The present invention relates to compositions comprising semi-crystalline beta-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and / or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and / or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a beta-1-4 conformation.
Owner:MARINE POLYMER TECH
Non-Flushing Niacin Analogues, and Methods of Use Thereof
ActiveUS20090312355A1Improve the level ofLower Level RequirementsBiocideNervous disorderArteriolar VasoconstrictionArterial Occlusive Diseases
One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.
Owner:TRUSTEES OF TUFTS COLLEGE
Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
ActiveUS8106011B1Rapid tissue oxygenationReduce ratePeptide/protein ingredientsPharmaceutical delivery mechanismArteriolar VasoconstrictionTissue oxygenation
Methods for preparation of a heat stable hemoglobin based oxygen-carrier-containing pharmaceutical composition such that beta-beta cross-linking is favored are provided. Using the methods of the present invention, the oxygen affinity of the resultant molecule can be controlled so that hemoglobin based oxygen carriers tailored for specific applications can be produced. Lower oxygen affinity crosslinked hemoglobin is useful for applications requiring rapid tissue oxygenation (e.g. hemorrhagic shock) while higher oxygen affinity cross-linked hemoglobin is useful for applications requiring a slower rate of oxygenation (e.g. cancer adjunct therapy). A highly purified and heat stable crosslinked non-polymeric tetrameric hemoglobin having beta-beta cross-linking of greater than 40-60% and suitable for use in mammals without causing renal injury and vasoconstriction is produced. A high temperature and short time (HTST) heat processing step is performed to effectively remove any undesired dimeric hemoglobin, non-crosslinked tetrameric hemoglobin, and plasma protein impurities.
Owner:BILLION KING INT
Magnetic resonance angiography method and magnetic resonance angiography system
InactiveCN103110420AQuality improvementImprove clinical utilityDiagnostic recording/measuringSensorsArteriolar VasoconstrictionPhase gradient
The invention discloses a magnetic resonance angiography method. The magnetic resonance angiography method includes applying a flowing sensitive dispersed phase gradient magnetic field in the readout direction and / or the phase encoding direction and / or the layer selection direction in a vasoconstriction period and then applying a residual magnetic moment removing gradient magnetic field after the flowing sensitive dispersed phase gradient magnetic field is applied; collecting blood flow images in the vasoconstriction period; collecting blood flow images in a vasodilatation period; and carrying out subtraction on the blood flow images in the vasoconstriction period and the blood flow images in the vasodilatation period to obtain blood flow images. The invention further discloses a magnetic resonance angiography system. According to the magnetic resonance angiography method and the magnetic resonance angiography system, in the specific implementation method, the flowing sensitive dispersed phase is used in the vasoconstriction period imaging process, so that intra-arterial self-spin dispersed phase can significantly lower arterial blood signals, and therefore the influence on imaging due to the velocity and the direction of blood flow can be reduced, high-quality peripheral arterial images can be obtained, and clinical practicability of the non-enhanced magnetic resonance angiography technology is improved.
Owner:SHENZHEN INST OF ADVANCED TECH
Control of Blood Vessel Physiology to Treat Skin Disorders
ActiveUS20100003353A1Convenient treatmentIncrease the number ofCosmetic preparationsBiocideArteriolar VasoconstrictionTissue architecture
In a method for treating an affected skin region of a patient having a skin disorder, a vasodilation composition is applied to an affected skin region of a patient, the affected skin region exhibiting a skin disorder characterized by at least one abnormal blood vessel, and the affected skin region is then treated so as to non-invasively disrupt tissue architecture, e.g., by inducing ischemia, of the at least one abnormal blood vessel. A vasoconstriction composition can then be applied to the skin region to cause vasoconstriction of the at least one blood vessel in order to promote healing.
Owner:BIOCHEMICS
Vasoconstriction compositions and methods of use
The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Owner:EYE THERAPIES
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com